BioNTech’s Stock Stuck Near Year Lows as Pumitamig Data Offers Litmus Test for Oncology Pivot

BioNTech shares languish near 52-week low as founders depart and cash burn accelerates; upcoming lung cancer trial results could validate or undermine its oncology pivot.

BioNTech is entering a period that will test whether investors’ faith in its transformation from a Covid-19 vaccine champion to an oncology powerhouse is justified. The stock is languishing close to its 52-week trough, the founders are heading for the exit, and the next major catalyst – a late-May readout from a pivotal lung cancer trial – could either vindicate the strategy or deepen the doubts.

The company’s share price closed at €76.95 on Friday, leaving it just 6.14 percent above the year’s low and 11.55 percent in the red over the past month. Both the 50-day moving average of €81.70 and the 200-day line at €86.94 sit well above the current level, underscoring a persistent weak trend. The market has been particularly unforgiving since March 10, when BioNTech announced that co-founders Ugur Sahin and Özlem Türeci will step down by year-end. The stock tumbled 18 percent that single day.

Sahin, the CEO, and Türeci, the chief medical officer, plan to launch a new mRNA venture, to which BioNTech will grant certain technology rights in exchange for a minority stake. No ongoing financial support is attached. The two sides aim to finalise a binding agreement by the end of June, while the supervisory board has already begun searching for successors. At the annual general meeting on May 15, shareholders voted overwhelmingly – with 92 percent of the capital present – to expand that board from six to eight seats, adding Iris Löw-Friedrich and Susanne Schaffert, both of whom bring deep experience in clinical development and oncology marketing. New chairman Helmut Jeggle made a point of stating that patents, brands and platforms are assets of the BioNTech group, not personal property of the founders.

The AGM also cleared a fresh authorised capital increase of up to 50 percent of existing shares, giving management financial flexibility for the swelling pipeline. That pipeline is burning cash at a rapid clip. Research and development costs in the first quarter alone topped $650 million, while vaccine revenue shrank to just $138 million, producing a sizeable net loss. For the full year 2026, BioNTech expects revenue in a range of €2.0 billion to €2.3 billion, with R&D spending of €2.2 billion to €2.5 billion – meaning development outlays will once again exceed sales.

Despite the red ink, the company’s balance sheet remains comfortable. At the end of the first quarter, liquid assets stood at €16.8 billion. On top of that, the AGM authorised a $1 billion share buyback programme running through May 2027, permitting repurchases of up to 4.2 percent of outstanding shares.

Analyst sentiment is notably more bullish than the share price suggests. Of 19 analysts covering the stock, 15 rate it a “Strong Buy” and four a “Hold”. Price targets range from $94 to $171. Berenberg’s Harry Gillis trimmed his target from $155 to $140 but maintained his buy recommendation, describing the stock as “significantly” undervalued.

The immediate test for that thesis arrives at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. BioNTech will present Phase 2 data from the ROSETTA-Lung-02 study on May 29, after the embargo on abstracts lifts on May 21. The spotlight falls on pumitamig, an experimental bispecific antibody being tested in combination with chemotherapy against the established standard pembrolizumab (Keytruda) plus chemo in first-line non-small cell lung cancer.

A strong result would provide external validation for the company’s pivot into oncology. Weak data would reinforce the doubts that have kept the stock under pressure. The readout is the first of seven late-stage data disclosures BioNTech has lined up for the year, and the company expects to have 15 Phase 3 trials running by year-end. In April it also struck a clinical collaboration with Boehringer Ingelheim to test pumitamig alongside obrixtamig, a DLL3/CD3 T-cell engager, in small cell lung cancer.

The second-quarter earnings report on August 4 will be the next milestone after ASCO. Until then, the pumitamig data represent the hardest test yet of whether BioNTech can convincingly reinvent itself once the pandemic windfall fades.